Viking Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	48.39	49.28	37.02	16.12	10.7
Research & Development	344.96	101.64	63.81	54.23	44.98
Operating Expenses	393.34	150.92	100.83	70.36	55.68
Operating Income	-393.34	-150.92	-100.83	-70.36	-55.68
Interest Expense	-0.06	-0.09	-0.09	-0.06	-0.02
Interest & Investment Income	33.7	40.94	15.02	1.59	0.7
Currency Exchange Gain (Loss)	-	-	-	-	0.01
EBT Excluding Unusual Items	-359.69	-110.08	-85.9	-68.83	-54.99
Gain (Loss) on Sale of Investments	0.06	0.11	-	-0.04	-
Pretax Income	-359.64	-109.96	-85.9	-68.87	-54.99
Net Income	-359.64	-109.96	-85.9	-68.87	-54.99
Net Income to Common	-359.64	-109.96	-85.9	-68.87	-54.99
Shares Outstanding (Basic)	113	109	94	77	77
Shares Outstanding (Diluted)	113	109	94	77	77
Shares Change (YoY)	3.33%	15.57%	22.79%	-0.47%	6.34%
EPS (Basic)	-3.19	-1.01	-0.91	-0.90	-0.71
EPS (Diluted)	-3.19	-1.01	-0.91	-0.90	-0.71
EBIT	-393.34	-150.92	-100.83	-70.36	-55.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.